JP2020536971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536971A5 JP2020536971A5 JP2020542056A JP2020542056A JP2020536971A5 JP 2020536971 A5 JP2020536971 A5 JP 2020536971A5 JP 2020542056 A JP2020542056 A JP 2020542056A JP 2020542056 A JP2020542056 A JP 2020542056A JP 2020536971 A5 JP2020536971 A5 JP 2020536971A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- coor
- halogen
- alkyl substituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C[C@@]1O[C@@](C*)C(*)C1 Chemical compound C[C@@]1O[C@@](C*)C(*)C1 0.000 description 54
- LKHAPZNNTXNFPN-DPHDGMEMSA-N C#C[C@@H]([C@@H]1OP(OC[C@H]([C@H]([C@H]2F)OP(OC3)(S)=O)O[C@H]2[n]2c(ncnc4N)c4nc2)(S)=O)O[C@H]3[C@H]1O Chemical compound C#C[C@@H]([C@@H]1OP(OC[C@H]([C@H]([C@H]2F)OP(OC3)(S)=O)O[C@H]2[n]2c(ncnc4N)c4nc2)(S)=O)O[C@H]3[C@H]1O LKHAPZNNTXNFPN-DPHDGMEMSA-N 0.000 description 1
- PDPYSCVBTHFLHR-LNCINSFHSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)O[C@H](COP(O[C@H]2[C@H](C#Cc3ccccc3)O[C@H](CO3)[C@H]2O)(S)=O)[C@H]1OP3(S)=O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)O[C@H](COP(O[C@H]2[C@H](C#Cc3ccccc3)O[C@H](CO3)[C@H]2O)(S)=O)[C@H]1OP3(S)=O PDPYSCVBTHFLHR-LNCINSFHSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572884P | 2017-10-16 | 2017-10-16 | |
| US62/572,884 | 2017-10-16 | ||
| PCT/US2018/056030 WO2019079261A1 (en) | 2017-10-16 | 2018-10-16 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536971A JP2020536971A (ja) | 2020-12-17 |
| JP2020536971A5 true JP2020536971A5 (enExample) | 2021-11-18 |
| JP7254821B2 JP7254821B2 (ja) | 2023-04-10 |
Family
ID=64110154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542056A Active JP7254821B2 (ja) | 2017-10-16 | 2018-10-16 | 抗がん剤としての環状ジヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11427610B2 (enExample) |
| EP (1) | EP3697801B1 (enExample) |
| JP (1) | JP7254821B2 (enExample) |
| KR (1) | KR102747388B1 (enExample) |
| CN (1) | CN111406063B (enExample) |
| ES (1) | ES2997757T3 (enExample) |
| WO (1) | WO2019079261A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019074887A1 (en) | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| US11945834B2 (en) * | 2018-03-08 | 2024-04-02 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| US12435104B2 (en) | 2019-07-25 | 2025-10-07 | Beigene, Ltd. | Cyclic dinucleotides as sting agonists |
| JPWO2021177123A1 (enExample) * | 2020-03-03 | 2021-09-10 | ||
| AU2021270750B2 (en) | 2020-05-13 | 2024-06-13 | Massachusetts Institute Of Technology | Compositions of polymeric microdevices and their use in cancer immunotherapy |
| WO2024211577A1 (en) | 2023-04-05 | 2024-10-10 | Massachusetts Institute Of Technology | Hybrid polymeric systems and methods of use thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005005450A1 (ja) * | 2003-07-15 | 2005-01-20 | Mitsui Chemicals, Inc. | 環状ビスジヌクレオシドの合成方法 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL2559690T3 (pl) | 2005-05-10 | 2016-09-30 | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania | |
| TWI382974B (zh) | 2005-12-20 | 2013-01-21 | 英塞特公司 | 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| SMT201900074T1 (it) | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR102181318B1 (ko) * | 2012-04-17 | 2020-11-20 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 화합물 및 방법 |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| PT2934598T (pt) * | 2012-12-19 | 2018-07-24 | Univ Texas | Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9549944B2 (en) * | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| WO2014189806A1 (en) * | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| ES2764178T3 (es) * | 2014-12-16 | 2020-06-02 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para inducción de citocinas |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MX2018001814A (es) * | 2015-08-13 | 2018-05-07 | Merck Sharp & Dohme | Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon. |
| CN114751950B (zh) * | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| AU2017378782A1 (en) * | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| AU2017378783A1 (en) * | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
-
2018
- 2018-10-16 EP EP18797354.0A patent/EP3697801B1/en active Active
- 2018-10-16 WO PCT/US2018/056030 patent/WO2019079261A1/en not_active Ceased
- 2018-10-16 JP JP2020542056A patent/JP7254821B2/ja active Active
- 2018-10-16 KR KR1020207013709A patent/KR102747388B1/ko active Active
- 2018-10-16 CN CN201880072955.4A patent/CN111406063B/zh active Active
- 2018-10-16 US US16/849,091 patent/US11427610B2/en active Active
- 2018-10-16 ES ES18797354T patent/ES2997757T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536897A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| JP2020532542A5 (enExample) | ||
| JP7602272B2 (ja) | Ｋｒａｓ関連がんを治療する方法 | |
| JP2020532529A5 (enExample) | ||
| KR101937501B1 (ko) | 치환된 2,3-디히드로이미다조[1,2-ｃ]퀴나졸린 염 | |
| JP2020532539A5 (enExample) | ||
| JP5881705B2 (ja) | Ｎａｍｐｔの阻害のための新規化合物及び組成物 | |
| JP2009513703A5 (enExample) | ||
| JP2020529400A5 (enExample) | ||
| JP2018504418A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| KR101671761B1 (ko) | 이미다조옥사진 화합물에 의한 항종양 효과 증강제 | |
| JP2014503567A5 (enExample) | ||
| JP2021513562A5 (enExample) | ||
| JP2014513704A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2010523681A5 (enExample) | ||
| KR20140059268A (ko) | 아미노-치환된 이미다조피리다진 | |
| IL319292A (en) | Cytotoxic imidazo[2,1-A]pyridine compounds and their use in therapy | |
| RU2012130929A (ru) | Гетероциклические соединения в качестве ингибиторов янус-киназы | |
| JP2018534289A5 (enExample) | ||
| HRP20220520T1 (hr) | Ciklički dinukleotidi kao agensi protiv raka | |
| JP2020527173A5 (enExample) |